Nov 5th, 3:12 pm
$PEN Q3 top line beat of $111.8M vs consensus $102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38M
Nov 6th, 9:15 am
$PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for $JNJ $MDT or even $EW
Wells Fargo med-tech analyst Larry Biegelsen has been all over this since Q1 below $100. $180 PT. RBC Capital initiated last month with $174 PT.
PEN
$PEN Q3 top line beat of $111.8M vs consensus $102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38M
Nov 6th, 9:15 am
$PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for $JNJ $MDT or even $EW
Wells Fargo med-tech analyst Larry Biegelsen has been all over this since Q1 below $100. $180 PT. RBC Capital initiated last month with $174 PT.
PEN